stockrowLegend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +126.1%
- Free cash flow
- −26.8%
- Total debt
- −49.6%
Quarter to June 2026, against a year earlier
Follow LEGN
Alert me
Legend Biotech Corporation Sponsored ADR (LEGN) EPS (diluted)
Legend Biotech Corporation Sponsored ADR's EPS (diluted) for fiscal 2025 was −$1.61, compared with −$0.97 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$0.50. Over the past ten years it has ranged from −$2.94 (fiscal 2023) to $0.07 (fiscal 2017); the current reading is higher than 56% of that period. Legend Biotech Corporation Sponsored ADR ranks 133rd of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.61 | — |
| FY2024 | −$0.97 | — |
| FY2023 | −$2.94 | — |
| FY2022 | −$2.81 | — |
| FY2021 | −$2.87 | — |
| FY2020 | −$2.57 | — |
| FY2019 | −$1.33 | — |
| FY2018 | −$0.03 | — |
| FY2017 | $0.07 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.17 | — |
| Mar 2026 | −$0.29 | — |
| Dec 2025 | −$0.16 | — |
| Sep 2025 | −$0.22 | — |
| 23 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | $0.22 |
| LEGN Legend Biotech Corporation Sponsored ADR | −$0.50 |
| IOVA Iovance Biotherapeutics, Inc. compare | −$0.53 |
| ABCL AbCellera Biologics Inc. compare | −$0.54 |
| TNGX Tango Therapeutics, Inc. compare | −$0.85 |
| RLAY Relay Therapeutics, Inc. compare | −$1.57 |
| EWTX Edgewise Therapeutics, Inc. compare | −$1.85 |
| DFTX Definium Therapeutics, Inc. compare | −$3.43 |
| DNTH Dianthus Therapeutics, Inc. compare | −$3.99 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on LEGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement